The "United States Adult Vaccine Market Report by Disease wise - Adult Vaccines Market, Disease wise - Numbers of Vaccinated Adults, States and Company Analysis, 2025-2033" report has been added to ResearchAndMarkets.com's offering.

United States Adult Vaccine Market is expected to reach US$ 11.10 billion by 2033 from US$ 6.55 billion in 2024, with a CAGR of 6.03% from 2025 to 2033.

Rising awareness, preventative healthcare activities, changing immunization programs, and the need for cutting-edge vaccines that treat infectious and chronic diseases are all expected to fuel the steady expansion of the US adult vaccine market. The U.S. adult vaccine market shows strong regional presence, with California, Texas, New York, and Florida leading adoption, driven by large populations, advanced healthcare infrastructure, and state-level support for preventive immunization programs.

Growing adult populations and increased awareness of disease prevention continue to fuel demand for vaccines against influenza, shingles, pneumococcal infections, and hepatitis. An aging population and an increase in lifestyle-related disease cases have highlighted the value of adult vaccination, broadening the market's reach. The industry's position has also been strengthened by the availability of cutting-edge vaccinations and the robust support of government immunization programs. Innovation in vaccination formulations, delivery systems, and distribution tactics is being fueled by growing partnerships among pharmaceutical corporations, healthcare providers, and research organizations.

According to data released by the Centers for Disease Control and Prevention in August 2024, for example, influenza affects around 8.8% of individuals in the United States who are between the ages of 18 and 64 annually.

The development of biotechnology and molecular research, which makes it possible to develop next-generation vaccines with improved efficacy and safety profiles, is another important factor. The growing demand for mRNA-based and recombinant vaccines in the US is a result of the quick incorporation of state-of-the-art research into adult vaccination programs. Broader accessibility is also influenced by changing healthcare funding and policy. To address unmet needs across a range of adult age groups, private companies are concurrently making significant investments in growing their product pipelines, clinical trials, and collaborations. These developments aid in the treatment of both infectious diseases and newly developing illnesses for which vaccinations may be useful.

The US adult vaccination market faces obstacles like pricing, supply chain issues, and vaccine reluctance despite its expansion. Public education campaigns, reliable delivery networks, and reasonably priced vaccine access are necessary to address these problems. However, the market for adult vaccines is expected to grow in the future due to the growing importance of preventative healthcare. This market will continue to grow as a result of the convergence of scientific developments, government initiatives, and demographic trends. It is anticipated that the US adult vaccine sector will increase its contribution to bettering health outcomes across the country with more knowledge, innovation, and legislative support.

Key Factors Driving the United States Adult Vaccine Market Growth

Rising Prevalence of Chronic and Infectious Diseases

The growing burden of both chronic and infectious diseases is a major factor propelling the U.S. adult vaccine market. With rising cases of influenza, shingles, hepatitis, and pneumococcal infections, vaccines are increasingly viewed as essential preventive tools. Additionally, chronic conditions such as diabetes and cardiovascular diseases compromise immunity, making adult populations more susceptible to infections.

As public awareness about the benefits of vaccines increases, more adults are seeking immunization to safeguard their long-term health. This demand is further supported by healthcare providers who actively recommend adult vaccination as part of preventive care. Pharmaceutical companies are responding by expanding their vaccine portfolios to address multiple diseases, ensuring a steady pipeline of effective solutions. This health-focused trend continues to strengthen the market's growth trajectory.

Advancements in Biotechnology and Vaccine Innovation

Technological progress in biotechnology has been pivotal in shaping the U.S. adult vaccine market. The development of recombinant, mRNA-based, and adjuvanted vaccines has set new standards for safety, efficacy, and long-lasting protection. These innovations have expanded the scope of immunization beyond traditional infectious diseases to include vaccines under development for conditions like cancer and autoimmune disorders. The rapid success of mRNA vaccines has encouraged pharmaceutical companies to invest in similar technologies for adult immunization.

Furthermore, advancements in delivery systems, such as intranasal and needle-free methods, are improving accessibility and patient compliance. Such innovations not only enhance adoption among adults but also drive competitive growth within the market. Continuous R&D investments are expected to expand therapeutic applications, creating long-term opportunities for expansion.

Government Programs and Preventive Healthcare Initiatives

The U.S. government's strong emphasis on preventive healthcare has been instrumental in driving adult vaccine adoption. Federal and state-level immunization programs, funding support, and awareness campaigns have expanded vaccine accessibility across diverse populations. Public health agencies actively promote adult vaccination as part of routine healthcare, with a focus on protecting vulnerable groups, including the elderly and immunocompromised individuals.

Partnerships between government agencies, healthcare providers, and private players have also enabled smoother distribution and outreach. Preventive healthcare initiatives, supported by insurance coverage for many vaccines, further encourage uptake. By integrating adult vaccination into broader healthcare policies, the government continues to create a favorable environment for the market. These efforts ensure not only public safety but also long-term cost savings in healthcare expenditure.

Challenges in the United States Adult Vaccine Market

Vaccine Hesitancy and Misinformation

One of the persistent challenges in the U.S. adult vaccine market is vaccine hesitancy, often fueled by misinformation, misconceptions about side effects, and distrust of pharmaceutical companies. Despite proven safety and efficacy, a segment of the adult population remains reluctant to receive vaccinations, which hampers overall coverage rates. Social media and misinformation campaigns amplify skepticism, creating hurdles for public health authorities and healthcare providers.

Overcoming hesitancy requires targeted educational initiatives, transparent communication, and community engagement to rebuild trust. While efforts are underway to combat misinformation, vaccine hesitancy remains a barrier that slows adoption, reduces market penetration, and impacts the broader effectiveness of immunization programs across adult populations.

High Costs and Access Barriers

The cost of adult vaccines and challenges in accessibility represent another significant market obstacle. While certain vaccines are covered by insurance, out-of-pocket expenses can deter many individuals, particularly in low-income groups. Additionally, disparities in healthcare infrastructure between urban and rural areas limit vaccine availability and distribution.

This unequal access prevents widespread adoption, even when awareness is high. Supply chain complexities, particularly during peak demand seasons, also affect timely availability. Addressing these barriers requires coordinated efforts between public and private stakeholders to reduce costs, strengthen infrastructure, and improve affordability. Without targeted strategies to expand equitable access, these challenges may continue to hinder full market growth and coverage across the United States.

Key Attributes:

Recent Developments in U.S. Adult Vaccine Market

• The FDA approved Moderna, Inc.'s mNEXSPIKE COVID-19 vaccine in May 2025 for use in treating people aged 12 to 64 in the United States.

Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis

• GlaxoSmithKline, plc.'s
• AstraZeneca plc
• Sanofi Pasteur's
• Pfizer, Inc.'s
• CSL Limited

Market Segmentations

Disease wise - Adult Vaccines Market

• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR (Measles, Mumps, and Rubella Vaccine)
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Travel and Miscellaneous
• Varicella

Disease wise - Numbers of Vaccinated Adults

• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Varicella

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

For more information about this report visit https://www.researchandmarkets.com/r/vn5fhv

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029177395/en/